EUVIMEDEUVIMED entdecken
Open Access

Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo

Lin Li, Xiaoyan Hu, Jewel Nkwocha, Maciej Kmieciak, Mark B Meads, Kenneth H Shain, Raghunandan R Alugubelli, Ariosto S Silva, Hashim Mann, Praneeth R Sudalagunta, Rafael R Canevarolo, Liang Zhou iD und 1 weitere

British Journal of Haematology · 2024-12 · 205 (6) · 2338-2348

DOI: 10.1111/bjh.19796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 08.10.2024. Verfasst von Lin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ataxia Telangiectasia Mutated Proteins, Multiple Myeloma, MAP Kinase Kinase 1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mechanisms underlying potentiation of the anti‐myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by MAPK (Mitogen‐activated protein kinases)‐related extracellular kinase 1/2 (MEK1/2) inhibitors were investigated. Co‐administration of the ATR inhibitor (ATRi) BAY1895344 (BAY) and MEK1/2 inhibitors, for example, cobimetinib, synergistically increased cell death in diverse MM cell lines. Mechanistically, BAY and cobimetinib blocked STAT3 Tyr705 and Ser727 phosphorylation, respectively, and dual dephosphorylation triggered marked STAT3 inactivation and downregulation of STAT3 (Signal transducer and activator of transcription 3) downstream targets (c‐Myc and BCL‐X L ). Similar events occurred in highly bortezomib‐resistant (PS‐R) cells, in the presence of patient‐derived conditioned medium, and with alternative ATR (e.g. M1774) and MEK1/2 (trametinib) inhibitors. Notably, constitutively active STAT3 c‐MYC or BCL‐X L ectopic expression significantly protected cells from BAY/cobimetinib. In contrast, transfection of cells with a dominant‐negative form of STAT3 (Y705F) sensitized cells to cobimetinib, as did ATR shRNA knockdown. Conversely, MEK1/2 knockdown markedly increased ATRi sensitivity. The BAY/cobimetinib regimen was also active against primary CD138 + MM cells, but not normal CD34 + cells. Finally, the ATR inhibitor/cobimetinib regimen significantly improved survival in MM xenografts, including bortezomib‐resistant models, with minimal toxicity. Collectively, these findings suggest that combined ATR/MEK1/2 inhibition triggers dual STAT3 Tyr705 and Ser727 dephosphorylation, pronounced downregulation of cytoprotective targets and MM cell death, warranting attention as a novel therapeutic strategy in MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorAtaxia Telangiectasia Mutated ProteinsMultiple MyelomaMAP Kinase Kinase 1HumansAnimalsMiceCell Line, TumorMAP Kinase Kinase 2AzetidinesXenograft Model Antitumor AssaysProtein Kinase InhibitorsPiperidinesMice, SCIDCell DeathDrug Synergism

Stichwörter der Autor:innen

ATR inhibitorSTAT3multiple myeloma

Substanzen

STAT3 Transcription FactorAtaxia Telangiectasia Mutated ProteinsATR protein, humanSTAT3 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2AzetidinesMAP2K1 protein, humanProtein Kinase Inhibitorscobimetinib

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Metabolism and Physiology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Translational Medicine, Asklepios BioPharmaceutical, Inc., Durham, North Carolina, USA.

ORCID-Profile: Liang Zhou, Steven Grant

Förderung

  • NCI NIH HHS
  • NIH/NCI

Zitieren

APA

Li, L., Hu, X., Nkwocha, J., Kmieciak, M., Meads, M. B., Shain, K. H., Alugubelli, R. R., Silva, A. S., Mann, H., Sudalagunta, P. R., Canevarolo, R. R., Zhou, L., & Grant, S. (2024). Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo. British Journal of Haematology, 205(6), 2338-2348. https://doi.org/10.1111/bjh.19796

Vancouver

Li L, Hu X, Nkwocha J, Kmieciak M, Meads MB, Shain KH, et al. Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo. British Journal of Haematology. 2024;205(6):2338-2348. doi:10.1111/bjh.19796

BibTeX
@article{Li2024,
  author = {Li, Lin and Hu, Xiaoyan and Nkwocha, Jewel and Kmieciak, Maciej and Meads, Mark B and Shain, Kenneth H and Alugubelli, Raghunandan R and Silva, Ariosto S and Mann, Hashim and Sudalagunta, Praneeth R and Canevarolo, Rafael R and Zhou, Liang and Grant, Steven},
  title = {Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {6},
  pages = {2338--2348},
  doi = {10.1111/bjh.19796}
}
Kostenlos starten →